{"DataElement":{"publicId":"4379789","version":"1","preferredName":"Hematology Hemoglobin Assessment Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator whether there was a hematology assessment for hemoglobin, the red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.","longName":"HMT_HGB_AS_CD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"3533989","version":"1","preferredName":"Hematology Hemoglobin Assessment","preferredDefinition":"information related to hematology assessment for hemoglobin, the red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.","longName":"HMT_HB_ASSESSMENT","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177090","version":"1","preferredName":"Hematology","preferredDefinition":"Hematology; the branch of medicine that deals with the blood and blood-forming organs and the diseases thereof.","longName":"Hematology","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Hematology","conceptCode":"C16673","definition":"The branch of medicine that deals with the blood and blood-forming organs and the diseases thereof.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7A70-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3533987","version":"1","preferredName":"Hemoglobin Physical Examination","preferredDefinition":"The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.:A physical examination is a systemic evaluation of the body and its functions using visual inspection, palpation, percussion, and auscultation, aimed to determine the presence or absence of physical signs of disease or abnormality for individual's health assessment.","longName":"C16676:C20989","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemoglobin","conceptCode":"C16676","definition":"The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Physical Examination","conceptCode":"C20989","definition":"A systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation. The purpose is to determine the presence or absence of physical signs of disease or abnormality for an individual's health assessment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C533BE39-7B9C-8D94-E040-BB89AD435D74","latestVersionIndicator":"Yes","beginDate":"2012-07-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-19","modifiedBy":"ONEDATA","dateModified":"2012-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C533BE39-7BAD-8D94-E040-BB89AD435D74","latestVersionIndicator":"Yes","beginDate":"2012-07-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876425","version":"1","longName":"Laboratory Data (including serologic/viral status)","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"HMT_HGB_AS_CD_IND","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Is pre-study hemoglobin great","type":"Preferred Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dl?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dl OR greater than or equal to 5.6 mmol/L?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 8 g/dl?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 90 g/L (or 9 g/dl)?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 10 g/dl?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than 9 g/dL?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 8 g/dL? ","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dL?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9.0 g/dL?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 10 g/dl and patient has not had blood transfusions in the 28 days prior to entry/randomization?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 10 g/dL with no blood transfusion in the past 28 days?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 8 g/dl, within 2 weeks of randomization?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dl, independent of transfusion for at least 7 days prior to screening and independent of growth factor support for at least 14 days prior to screening?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 10 g/dl within 4 weeks prior to administration of study treatment  and patient has not had blood transfusions (packed red blood cells and platetet transfusions) in the past 28 days?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dl without transfusion for at least 7 days prior to screening?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 8 g/dL within 2 weeks of the initiation of treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dl (patients may be transfused to this level)?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than 10 g/dl within 4 weeks prior to administration of study treatment  and patient has not had blood transfusions (packed red blood cells and platelet transfusions) in the past 28 days?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 10 g/dl within 28 days prior to administration of study treatment  and patient has not had blood transfusions (packed red blood cells and platelet transfusions) in the past 28 days?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dl for mono-therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 10 g/dl with no blood transfusion  within 28 days prior to administration of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dL or if anemia is related to bone marrow involvement with lymphoma is hemoglobin greater than or equal to 8 g/dL?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 8 g/dl, within 7 days before starting treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"If patient has been assigned to receive Veliparib, is hemoglobin greater than or equal to 10.0 g/dL and patient has had no blood transfusions in the past 28 days?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 8 g/d, unless there is documented bone marrow involvement by lymphoma?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Is screening visit hemoglobin greater than or equal to 8 g/dL?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dl (no transfusions in past 2 weeks)?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 8 g/dL (within 14 days of enrollment)?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than 8 g/dL?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 10.0 g/dL and patient has had no blood transfusions in the past 28 days?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 10 g/dL with no packed red blood cell transfusion in the 14 days prior to starting therapy?","url":null,"context":"Theradex"},{"name":"Theradex -30","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 80 g/L (or 8 g/dl)?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 10 g/dL with no blood transfusions within the past 28 days?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 10 g/dL (within 7 days of study drug initiation) with no blood transfusion in the past 28 days?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dL (greater than or equal to 8.0 g/dL for gastric cancer [GC] only), within 8 days of enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dL (without transfusion within 1 week preceding study drug administration)?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Is pre-study hemoglobin 8 g/dl?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dL or 5.6 mmol/L without transfusion or erythropoietin dependency (within 7 days of assessment)?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9.5 g/dL and transfusion independent (defined as not requiring more than 2 units of red blood cell (RBC) transfusions during the 4-week period prior to screening)?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Does patient have pre-study hemoglobin greater than or equal to 10 g/dl within 14 days of randomization/enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dl independent of transfusion, within 14 days prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 8 g/dL or greater than or equal to 5.6 mmol/L?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9.0 g/dL (greater than or equal to 8.0 g/dL for gastric cancer [GC] only) within 14 days of enrollment and no transfusions with red blood cells or platelets within 1 week prior to screening assessment?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dL within 2 weeks of enrollment with no blood transfusion in the past 4 weeks?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dL or 5.6 mmol/L?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dl (stable for 2 weeks without transfusion or erythropoiesis-stimulating agent), within 14 days prior to study registration?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dl OR greater than or equal to 5.6 mmol/L, without packed red blood cell (pRBC) transfusion within the prior 2 weeks?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 10 g/dL, blood transfusion to reach desired level must be at least 14 days prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than 5.0 mmol/L (greater than 8.0 g/dL)?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dL (patients may be transfused to achieve this value)?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Is pre-study hemoglobin greater than or equal to 9 g/dl OR greater than or equal to 5.6 mmol/L, without packed red blood cell (pRBC) transfusion within the prior 14 days of registration?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6B11-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-12-13","changeDescription":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}